English
Русский 22-33 p.
The problem of mineral metabolism in chronic renal failure is becoming a public health problem in all countries of the world, which is associated with an increase in the overall survival of this category of patients. We have carried out a comprehensive study of mineral metabolism and some biomarkers of bone metabolism in the initial and terminal stages of chronic kidney disease. At the same time, we examined not only the baseline values, but also the indicators after the treatment. It was determined that after treatment some stabilization of the studied parameters is noted, however, in most cases of observations, they remain higher than in the control group. Based on the above literature review, our statistical data and their comparisons with the studies of other authors, we are more inclined to the concept of using a complex of biomarkers in the study of the state of mineral metabolism in patients with chronic kidney disease.
1. Ortiz A. et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. The lancet. 2014. № 383. P. 1831 – 1843.
2. Moe S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2006. № 69. P. 1945 – 1953.
3. Fang Y. et al. CKD-induced wingless/Integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. Journal of the American Society of Nephrology. 2014. № 25. P. 1760 – 1773.
4. Katrin Uhlig et al. (2009) Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney international. Supplement, 113, S1.
5. Scialla J.J. et al. Mineral metabolites and CKD progression in African Americans. Journal of the American Society of Nephrology. 20013. № 24. P. 125 – 135.
6. Hill K.M. et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney international. 2013. № 83. P. 959 – 966.
7. Wesseling K., Bakkaloglu S., Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatric Nephrology. 2008. № 23. P. 195 – 207.
8. Evenepoel P. et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. American Journal of Transplantation. 2014. № 14. P. 2545 – 2555.
9. Malluche H.H., Porter D.S., Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nature Reviews Nephrology. 2013. № 9. P. 671.
10. Kawakami T., Ren S., Duffield J.S. Wnt signalling in kidney diseases: dual roles in renal injury and repair. The Journal of pathology. 2013. № 229. P. 221 – 231.
11. Morena M. et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Nephrology Dialysis Transplantation. 2015. № 30. P. 1345 – 1356.
12. Pelletier S. et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clinical Journal of the American Society of Nephrology. 2013. № 8. P. 819 – 823.
13. Uryas'ev O.M. i dr. Osteoporoz i revmatoidnyj artrit (po rezul'tatam programmy «Osteoskrining Rossii»). Zemskij vrach. 2017. № 1. C. 38 – 40.
14. Egshatyan L.V., Mokrysheva N.G., Rozhinskaya L.YA. Vtorichnyj i tretichnyj giperparatireoz pri hronicheskoj bolezni pochek. Osteoporoz i osteopatii. 2017. № 20. S. 63 – 68.
15. Ahmatov V.Yu. i dr. Funkcional'naya aktivnost' nejtrofilov i pokazateli fosfornokal'cievogo gomeostaza u bol'nyh hronicheskoj pochechnoj nedostatochnost'yu, nahodyashchihsya na pro-grammnom gemodialize. Vestnik CHelyabinskoj oblastnoj klinicheskoj bol'nicy. 2016. № 1. S. 29 – 32.
16. Milovanov Yu.S., Fomin V.V., Milovanova L.YU. Trudnosti korrekcii giperfosfatemii u bol'nyh hronicheskoj pochechnoj nedostatochnost'yu. Mesto ne soderzhashchih kal'cij fosforsvyazyva-yushchih preparatov. Terapevticheskij arhiv (arhiv do 2018 g.). 2016. № 88. S. 95 – 100.
17. Pavlov S.B., Zukow W. Violation of collagen metabolism in the development of renal scarring in patients with chronic pyelonephritis= Narushenie obmena kollagena pri razvitii nefroskleroza u bol'nyh hronicheskim pielonefritom, Journal of Education. Health and Sport. 2016. № 6. P. 263 – 278.
18. Velichko A.V. i dr. Pokazateli kostnogo metabolizma u pacientov s vtorichnym giperparatireozom na fone hronicheskoj bolezni pochek. Hirurgiya Vostochnaya Evropa. 2015. № 4. S. 92 – 99.
19. Bergman A. et al. Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. Journal of nephrology. 2017. № 30. P. 255 – 262.
20. Milovanova L.Yu., Milovanov Yu.S. (2014) Mineral'nye i kostnye narusheniya pri hronicheskoj bolezni pochek. Profilaktika i lechenie. Infra-M, 2014. № 40. S. 90 – 95.
21. Ketteler M. et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Annals of internal medicine. 2018. № 168. P. 422 – 430.
2. Moe S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2006. № 69. P. 1945 – 1953.
3. Fang Y. et al. CKD-induced wingless/Integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. Journal of the American Society of Nephrology. 2014. № 25. P. 1760 – 1773.
4. Katrin Uhlig et al. (2009) Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney international. Supplement, 113, S1.
5. Scialla J.J. et al. Mineral metabolites and CKD progression in African Americans. Journal of the American Society of Nephrology. 20013. № 24. P. 125 – 135.
6. Hill K.M. et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney international. 2013. № 83. P. 959 – 966.
7. Wesseling K., Bakkaloglu S., Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatric Nephrology. 2008. № 23. P. 195 – 207.
8. Evenepoel P. et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. American Journal of Transplantation. 2014. № 14. P. 2545 – 2555.
9. Malluche H.H., Porter D.S., Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nature Reviews Nephrology. 2013. № 9. P. 671.
10. Kawakami T., Ren S., Duffield J.S. Wnt signalling in kidney diseases: dual roles in renal injury and repair. The Journal of pathology. 2013. № 229. P. 221 – 231.
11. Morena M. et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Nephrology Dialysis Transplantation. 2015. № 30. P. 1345 – 1356.
12. Pelletier S. et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clinical Journal of the American Society of Nephrology. 2013. № 8. P. 819 – 823.
13. Uryas'ev O.M. i dr. Osteoporoz i revmatoidnyj artrit (po rezul'tatam programmy «Osteoskrining Rossii»). Zemskij vrach. 2017. № 1. C. 38 – 40.
14. Egshatyan L.V., Mokrysheva N.G., Rozhinskaya L.YA. Vtorichnyj i tretichnyj giperparatireoz pri hronicheskoj bolezni pochek. Osteoporoz i osteopatii. 2017. № 20. S. 63 – 68.
15. Ahmatov V.Yu. i dr. Funkcional'naya aktivnost' nejtrofilov i pokazateli fosfornokal'cievogo gomeostaza u bol'nyh hronicheskoj pochechnoj nedostatochnost'yu, nahodyashchihsya na pro-grammnom gemodialize. Vestnik CHelyabinskoj oblastnoj klinicheskoj bol'nicy. 2016. № 1. S. 29 – 32.
16. Milovanov Yu.S., Fomin V.V., Milovanova L.YU. Trudnosti korrekcii giperfosfatemii u bol'nyh hronicheskoj pochechnoj nedostatochnost'yu. Mesto ne soderzhashchih kal'cij fosforsvyazyva-yushchih preparatov. Terapevticheskij arhiv (arhiv do 2018 g.). 2016. № 88. S. 95 – 100.
17. Pavlov S.B., Zukow W. Violation of collagen metabolism in the development of renal scarring in patients with chronic pyelonephritis= Narushenie obmena kollagena pri razvitii nefroskleroza u bol'nyh hronicheskim pielonefritom, Journal of Education. Health and Sport. 2016. № 6. P. 263 – 278.
18. Velichko A.V. i dr. Pokazateli kostnogo metabolizma u pacientov s vtorichnym giperparatireozom na fone hronicheskoj bolezni pochek. Hirurgiya Vostochnaya Evropa. 2015. № 4. S. 92 – 99.
19. Bergman A. et al. Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. Journal of nephrology. 2017. № 30. P. 255 – 262.
20. Milovanova L.Yu., Milovanov Yu.S. (2014) Mineral'nye i kostnye narusheniya pri hronicheskoj bolezni pochek. Profilaktika i lechenie. Infra-M, 2014. № 40. S. 90 – 95.
21. Ketteler M. et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Annals of internal medicine. 2018. № 168. P. 422 – 430.